4-[4-({4,4-dimethyl-2-[3-(trifluoromethyl)phenyl]cyclohex-1-en-1-yl}methyl)piperazin-1-yl]-2-(1H-indol-4-yloxy)-N-({3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl}sulfonyl)benzamide | 1228782-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-[4-({4,4-dimethyl-2-[3-(trifluoromethyl)phenyl]cyclohex-1-en-1-yl}methyl)piperazin-1-yl]-2-(1H-indol-4-yloxy)-N-({3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl}sulfonyl)benzamide
• 英文别名: 4-[4-[[4,4-dimethyl-2-[3-(trifluoromethyl)phenyl]cyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1H-indol-4-yloxy)-N-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide
• CAS: 1228782-01-1
• 化学式: C₄₈H₅₄F₃N₇O₆S
• 分子量: 914.061
• InChiKey: LNKCZIXHBDSYJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.5
• 重原子数：
  65
• 可旋转键数：
  14
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  164
• 氢给体数：
  3
• 氢受体数：
  13

文献信息

• BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
  申请人：Bruncko Milan

  公开号：US20100152183A1

  公开（公告）日：2010-06-17

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

  本发明涉及抑制抗凋亡Bcl-2或Bcl-xL蛋白活性的化合物，含有该化合物的组合物，以及治疗表达抗凋亡Bcl-2蛋白的疾病的方法。
• BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
  申请人：ABBVIE INC.

  公开号：US20130296295A1

  公开（公告）日：2013-11-07

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

  本发明涉及一种抑制抗凋亡Bcl-2或Bcl-xL蛋白活性的化合物，包含该化合物的组合物以及治疗表达抗凋亡Bcl-2蛋白疾病的方法。
• PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE
  申请人：AbbVie Inc.

  公开号：EP3666758A1

  公开（公告）日：2020-06-17

  Disclosed is a process for the preparation of the compound of formula (471)

  公开了一种制备式（471）化合物的工艺
• Chemical entities that kill senescent cells for use in treating age-related disease
  申请人：Unity Biotechnology, Inc.

  公开号：US10195213B2

  公开（公告）日：2019-02-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

  本文公开的化合物可有效治疗与衰老有关的各种疾病状态。所公开的化合物可用于消除衰老细胞以治疗疾病。化合物的给药方式包括单次给药和循环给药。
• SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
  申请人：Abbott Laboratories

  公开号：EP2376480A2

  公开（公告）日：2011-10-19